| Titolo | Fase | Stato | Sede patologia | Strutture coinvolte | Dettaglio |
Potenziale ruolo protettivo degli inibitori di SGLT-2 sulla cardiotossicità indotta da chemoterapia (PROTECT trial) |
II |
in corso |
Cancro della mammella |
- SC Cardiologia |
|
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical) |
III |
in corso |
Cancro della cervice uterina localmente avanzato |
- SC Oncologia Clinica Sperimentale Uro - Ginecologica |
|
A PHASE III, OPEN-LABEL, RANDOMISED STUDY OF NEOADJUVANT DATOPOTAMAB DERUXTECAN (DATO-DXD) PLUS DURVALUMAB FOLLOWED BY ADJUVANT DURVALUMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS NEOADJUVANT PEMBROLIZUMAB PLUS CHEMOTHERAPY FOLLOWED BY ADJUVANT PEMBROLIZUMAB WITH OR WITHOUT CHEMOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED TRIPLE-NEGATIVE OR HORMONE RECEPTOR-LOW/HER2-NEGATIVE BREAST CANCER |
III |
in corso |
CARCINOMA MAMMARIO |
- SC Oncologia Clinica Sperimentale di Senologia |
|
A PHASE III, RANDOMIZED, CONTROLLED, GLOBAL MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL TINENGOTINIB VERSUS PHYSICIAN’S CHOICE IN SUBJECTS WITH FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR)-ALTERED, CHEMOTHERAPY- AND FGFR INHIBITOR-REFRACTORY/RELAPSED CHOLANGIOCARCINOMA (FIRST-308) |
III |
in corso |
COLANGIOCARCINOMA |
- SC Oncologia Clinica Sperimentale Addominale |
|
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) |
III |
in corso |
CANCRO PROSTATA |
- SC Oncologia Clinica Sperimentale Uro - Ginecologica |
